Shareholder Alert: Ademi LLP investigates whether Intra-Cellular Therapies, Inc. is obtaining a Fair Price for its Public Shareholders

MILWAUKEE--(BUSINESS WIRE)--Ademi LLP is investigating Intra-Cellular Therapies (Nasdaq: ITCI) for possible breaches of fiduciary duty and other violations of law in its transaction with Johnson & Johnson.

Click here to learn how to join our investigation and obtain additional information or contact us at [e-mail] or toll-free: 866-264-3995. There is no cost or obligation to you.

In the transaction, Intra-Cellular Therapies stockholders will receive only $132.00 per share in cash for a total equity value of approximately $14.6 billion. Intra-Cellular Therapies insiders will receive substantial benefits as part of change of control arrangements.

The transaction agreement unreasonably limits competing transactions for Intra-Cellular Therapies by imposing a significant penalty if Intra-Cellular Therapies accepts a competing bid. We are investigating the conduct of Intra-Cellular Therapies’ board of directors, and whether they are fulfilling their fiduciary duties to all shareholders.

We specialize in shareholder litigation involving buyouts, mergers, and individual shareholder rights. For more information, please feel free to call us. Attorney advertising. Prior results do not guarantee similar outcomes.